Surgeries & Interventions July 10, 2023
The First Dissolvable Heart Monitor and Pacer July 10, 2023
A team of Northwestern and George Washington scientists took a big step towards revolutionizing how patients are monitored and treated after major cardiac events, unveiling the first dissolvable cardiac mapping and pacing device.
Artificial Intelligence July 6, 2023
Improving Occlusion MI Detection with ECG AI July 6, 2023
A University of Pittsburgh-led team developed an ECG-based AI model capable of detecting occlusion myocardial infarction, showing that it improves both OMI detection and assessments, and finding that it has real clinical potential.
Cardiology Pharmaceuticals June 29, 2023
Two Sides to Bempedoic Acid’s Primary Prevention Impact June 29, 2023
A Cleveland Clinic-led study stunned the ADA 2023 crowd this week, showing that bempedoic acid (Esperion’s Nexletol) significantly reduced future cardiovascular events among people with high CVD risks who had never experienced a major cardiac event.
Surgeries & Interventions June 26, 2023
How to Assess the Abiomed Impella Pump June 26, 2023
Abiomed’s Impella pump is being used across America to support patients with acute myocardial infarction with cardiogenic shock (AMICS) - but do we know it’s safe and effective?
Cardiology Pharmaceuticals June 22, 2023
Agepha’s Lodoco FDA-Approved for CVD Inflammation June 22, 2023
Agepha Pharma’s Lodoco (colchicine) just became the first anti-inflammatory drug to land FDA approval for reducing cardiovascular event risks, marking a major milestone in the emerging field of CVD inflammation treatment.
Cardiology Pharmaceuticals June 20, 2023
NYU’s Atherosclerosis Inflammation Discovery June 20, 2023
NYU researchers discovered that AstraZeneca’s saracatinib - an investigational drug originally developed to treat cancer - could slow atherosclerosis progression by addressing inflammation that we know contributes to ASCVD and haven't figured out how to treat.
Cardiology Policy June 15, 2023
Glenfield Hospital’s Nurse-Performed TAVI Uproar June 15, 2023
Glenfield Hospital Cardiology, just outside Leicester in the UK, set cardiology channels ablaze earlier this week with a celebratory tweet announcing that one of its advanced nurse practitioners performed a whole TAVI procedure (aka TAVR in the U.S.) as the first operator.
Cardiology Pharmaceuticals June 12, 2023
Bitterroot Bio’s Cardio-Immunology Mission June 12, 2023
Bitterroot Bio emerged last week, announcing a massive $145M Series A round and an equally massive mission to “rewrite the practice of cardiology” through cardio-immunology therapeutics.
Cardiology Guidelines June 8, 2023
Questioning Antihypertensives for Older Patients June 8, 2023
When clinicians find that an older hospitalized patient has elevated blood pressure, their next step is often to initiate antihypertensive treatment, but a new JAMA Internal Medicine study suggests that many of these patients would be better off having their BPs left unmanaged.
Cardiology Pharmaceuticals June 5, 2023
Lexicon’s Lands Long-Awaited HF Approval June 5, 2023
Lexicon Pharmaceuticals’ Inpefa (sotagliflozin) just became the first FDA-approved dual SGLT2 / SGLT1 inhibitor for treating heart failure, landing a wide-ranging approval that could alter the HF treatment arena.
Remote Care June 1, 2023
UCSD’s Wearable Cardiac Ultrasound Milestone June 1, 2023
A team of UCSD scientists took a major step towards changing how, when, and where cardiac ultrasound exams are performed, unveiling the first fully integrated wearable ultrasound system intended for continuous heart monitoring.
Remote Care May 25, 2023
Remote Cardiac Monitoring Gains Momentum May 25, 2023
The last week featured two of the world’s largest heart failure and electrophysiology conferences, each driving a surge of new papers and studies suggesting that remote monitoring is moving to the forefront of both cardiology subspecialties.
Cardiology Pharmaceuticals May 22, 2023
SCOTUS Rules Against Amgen in PCSK9 Patent Dispute May 22, 2023
The U.S. Supreme Court ruled against Amgen in its PCSK9 inhibitor patent dispute with Sanofi and Regeneron that was intended to revive patents for Amgen’s cholesterol-lowering drug, Repatha.
Cardiology Pharmaceuticals May 18, 2023
Amarin Vascepa’s Coronary Physiology Improvements May 18, 2023
Amarin presented results from the latest study on its Vascepa CVD medication (icosapent ethyl, aka IPE), suggesting that IPE improves users' coronary physiology.
Artificial Intelligence May 15, 2023
Philips Expands into Echo AI with DiA Acquisition May 15, 2023
Philips took a major step towards automating and expanding access to echo ultrasound exams, acquiring echo AI startup DiA Imaging Analysis.
Cardiology Pharmaceuticals May 11, 2023
AstraZeneca’s Farxiga Lands Heart Failure FDA Extension May 11, 2023
AstraZeneca’s Farxiga (dapagliflozin) oral SGLT2 inhibitor just landed FDA approval for a far wider range of heart failure patients, now covering risk reduction among all adults with HF -- regardless of their left ventricular ejection fraction status.
Cardiology Pharmaceuticals May 8, 2023
Tirzepatide Delivers in SURMOUNT-2 May 8, 2023
Results from Eli Lilly’s SURMOUNT-2 trial are in, and they further confirmed that its GLP-1 agonist tirzepatide drives meaningful weight loss among obese or overweight adults with type 2 diabetes.
Preventive Cardiology May 4, 2023
Unraveling Depression’s CVD Link May 4, 2023
People with depression have up to 72% higher risks of developing cardiovascular disease, but there’s still many scientific blindspots regarding the links between depression and CVD. Two new studies added visibility to those blindspots, particularly related to prenatal depression and psychotherapy.
Cardiology Pharmaceuticals May 1, 2023
A Case for Antihypertensive Polypills May 1, 2023
A new JAMA Cardiology study suggests that many hypertension patients could benefit from beginning their treatment with “polypills” featuring a combination of three or four low-dose antihypertensives, rather than starting with one or two BP-lowering agents and escalating if they don’t prove effective.
